£5 Million Fuels Imperagen’s Quantum AI Enzyme Engineering Platform

Imperagen, a techbio spin-out from the University of Manchester, has secured £5 million in seed funding led by PXN Ventures, bringing the company’s total funding to £8.5 million. The investment will fuel expansion of Imperagen’s research and development, particularly its “wet lab” capabilities, over the next 18 months as it advances a novel enzyme engineering platform. This platform combines quantum physics simulations of millions of mutation combinations with a self-improving AI system and automated robotics, aiming to overcome the limitations of traditional and recent enzyme design methods. New CEO Guy Levy-Yurista, PhD, explains that companies making a radical difference in the emerging AI-driven future are AI-native, lean on real world data, have genuine impact, and are fundamentally deep tech. Imperagen’s technology has already demonstrated significant improvements, boosting the productivity of two enzymes by a factor of 677 and 572, respectively, in just five rounds.

Quantum Physics & AI Drive Enzyme Engineering

Imperagen is developing a novel approach to enzyme engineering, leveraging quantum physics to simulate millions of mutation combinations in silico as the initial step in its proprietary platform. This computational stage addresses limitations found in both traditional manual screening methods and more recent enzyme engineering techniques, which often struggle with real-world application. The company’s system trains problem-specific AI models, refining them with data generated from physical experiments, rather than relying on broadly applicable AI. Imperagen integrates automated robotics to rapidly test predictions in the lab, creating a closed-loop system where experimental results directly inform and improve the AI’s predictive capabilities. This recursive process allows the platform to become increasingly accurate with each iteration, a characteristic the company believes is essential for industrial-scale enzyme development. The recent £5 million seed funding round brings total investment to £8.5 million.

Closed-Loop System Integrates Simulation, AI, and Wet Lab Testing

Imperagen distinguishes itself from conventional enzyme engineering approaches, both manual screening and recent methods, by integrating in silico quantum physics simulations with artificial intelligence and automated laboratory testing within a single, iterative system. The platform begins by leveraging quantum physics to model and generate a substantial dataset of predicted enzyme properties before any physical experimentation takes place. These simulated results then serve as training data for specialized AI models, designed to address specific engineering challenges and calibrated accordingly. Crucially, the system doesn’t remain confined to prediction; automated robotics rigorously tests the highest-performing predicted variants in a “wet lab” environment, generating real-world experimental data. This data is actively fed back into the AI model, enabling continuous refinement and improvement with each cycle, and is intended to address the limitations of predictability and speed that plague traditional methods and some emerging AI-driven techniques. Guy Levy-Yurista, the newly appointed CEO, described this process.

677x & 572x Productivity Gains in Initial Enzyme Projects

Imperagen is demonstrating substantial gains in enzyme engineering through a novel platform integrating quantum physics, artificial intelligence, and automated laboratories. Initial projects have yielded productivity improvements of 677-fold and 572-fold for two distinct enzymes, achieved within a remarkably swift five rounds of iterative design and testing. The company’s system begins by simulating millions of mutation combinations in silico using quantum physics, generating a dataset used to train specialized AI models. These AI models are tailored to specific engineering challenges, rather than relying on broadly applicable algorithms, and are continuously refined by data from automated laboratory experiments. The company recently collaborated with a Fortune 500 personal care firm seeking to develop a new product line, providing a practical demonstration of the platform’s capabilities.